{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:12Z","timestamp":1793656512695,"version":"4.5.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed\/refractory (R\/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R\/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019510","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:54:44Z","timestamp":1776880484000},"page":"4427-4438","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis"],"prefix":"10.1182","volume":"10","author":[{"given":"Yu","family":"Yagi","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-2008","authenticated-orcid":false,"given":"Yusuke","family":"Kanemasa","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3346","authenticated-orcid":false,"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kato","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-7909","authenticated-orcid":false,"given":"Ryo","family":"Hanajiri","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"6Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2422","authenticated-orcid":false,"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[{"name":"8Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3778","authenticated-orcid":false,"given":"Toshihiro","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-723X","authenticated-orcid":false,"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"13Hematology and Hematopoietic Cell Transplantation, Osaka Metropolitan University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-4467","authenticated-orcid":false,"given":"Akiyo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"14Division of Transfusion Medicine, Kanazawa University Hospital, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Institute of Science Tokyo Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6299-4266","authenticated-orcid":false,"given":"Haryoon","family":"Kim","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"16Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"16Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-9973","authenticated-orcid":false,"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hokkaido University Hospital, Sapporo, Japan"},{"name":"17Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"18Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"19Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"1","key":"2026071409574442300_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2026071409574442300_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"2026071409574442300_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"2026071409574442300_bib4","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"issue":"27","key":"2026071409574442300_bib5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026071409574442300_bib6","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"2026071409574442300_bib7","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","article-title":"Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2026071409574442300_bib8","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2026071409574442300_bib9","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2026071409574442300_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026071409574442300_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"27","key":"2026071409574442300_bib12","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026071409574442300_bib13","first-page":"581.e1","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026071409574442300_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.20.01616","article-title":"How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T-cell therapies","volume":"39","author":"Reagan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026071409574442300_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjh.19157","article-title":"Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time","volume":"204","author":"Boyle","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"2026071409574442300_bib16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41409-025-02722-y","article-title":"Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy","volume":"60","author":"Torrent","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026071409574442300_bib17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"2026071409574442300_bib18","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"2026071409574442300_bib19","first-page":"193","article-title":"Establishment of a cellular therapy registry in Japan, a platform for data sharing for research, industry, and regulatory use","volume":"11","author":"Atsuta","year":"2022","journal-title":"J Hematopoietic Cell Transpl"},{"key":"2026071409574442300_bib20","first-page":"233","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Stein","year":"2008","edition":"4th ed"},{"issue":"7","key":"2026071409574442300_bib21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2026071409574442300_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026071409574442300_bib23","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026071409574442300_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026071409574442300_bib25","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2026071409574442300_bib26","first-page":"77.e71","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"21","key":"2026071409574442300_bib27","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","article-title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","volume":"9","author":"Desch\u00eanes-Simard","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409574442300_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Dubnikov Sharon","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2026071409574442300_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2025017120","article-title":"Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium","volume":"10","author":"Wang","year":"2026","journal-title":"Blood Adv"},{"issue":"11","key":"2026071409574442300_bib30","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026071409574442300_bib31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/bjh.70090","article-title":"Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma","volume":"207","author":"Morimoto","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"2026071409574442300_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A multicenter real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in large B-cell lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2026071409574442300_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41409-026-02802-7","article-title":"Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy","volume":"61","author":"Yagi","year":"2026","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026071409574442300_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41409-024-02427-8","article-title":"Role of bridging RT in relapsed\/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study","volume":"60","author":"Bramanti","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2026071409574442300_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.19453","article-title":"Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK","volume":"205","author":"Kuhnl","year":"2024","journal-title":"Br J Haematol"},{"issue":"13","key":"2026071409574442300_bib36","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study","volume":"9","author":"Yegya-Raman","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026071409574442300_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4427\/2529726\/blooda_adv-2025-019510-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4427\/2529726\/blooda_adv-2025-019510-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:51Z","timestamp":1784037471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4427\/567922\/Drivers-of-temporal-improvement-in-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019510","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,24]]}}}